DAVID S. GRAYZEL
CIK 1732786 · last filed 2026-01-30
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$0
Companies
3
Total Filings
24
Lifetime Open-Market Net
-$35.87M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| QTTB | Director | — | $12.64 | — | $0 | 5 | 2026-01-30 |
| Jade Biosciences, Inc. (AVTE) Delisted | Director | 1,784,730 | $93.80 | $167.41M | $7.17M | 9 | 2024-06-07 |
| Surface Oncology, Inc. (SURF) Delisted | Director | 0 | $1.07 | $0 | -$43.04M | 10 | 2023-09-08 |
Recent Filings · Page 3 of 3
24 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2019-10-03 | Surface Oncology, Inc. (SURF) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-07-02 | Surface Oncology, Inc. (SURF) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-06-06 | Surface Oncology, Inc. (SURF) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-04-23 | Surface Oncology, Inc. (SURF) Delisted | Mixed | +3,281,817 | $1.50M | EDGAR |
Showing 21–24 of 24
Prev
Page 3 of 3
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.